НовостиBenzingaGuggenheim Initiates Coverage On Retension Pharmaceuticals with Buy Rating, Announces Price Target of $55 Guggenheim Initiates Coverage On Retension Pharmaceuticals with Buy Rating, Announces Price Target of $55 Benzinga 2026.11.02 14:05 (GMT+0) Открыть на Benzinga Другие новости